A triple tumor study of MAGE-A10 SPEAR T-cell therapy in patients with inoperable or metastatic urothelial cancer, melanoma, or squamous cell carcinoma of the head and neck

Trial Profile

A triple tumor study of MAGE-A10 SPEAR T-cell therapy in patients with inoperable or metastatic urothelial cancer, melanoma, or squamous cell carcinoma of the head and neck

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs MAGE A-10 TCR-transduced lymphocytes (Primary)
  • Indications Bladder cancer; Head and neck cancer; Malignant melanoma; Ovarian cancer; Renal cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Adaptimmune
  • Most Recent Events

    • 08 Jan 2018 According to an Adaptimmune media release, three patients have been dosed in the first cohort.
    • 08 Jan 2018 According to an Adaptimmune media release, based on the review by the independent safety review committee (SRC), the company has decided to escalate to the next dose of 1 billion transduced MAGE-A10 SPEAR T-cells in this trial. The decision to escalate in the NSCLC cohort will be reviewed by the SRC following dosing of the 6th patient.
    • 08 Jan 2018 Results published in an Adaptimmune Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top